[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study

[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study

Abstract Background During anthracycline treatment of cancer, there is a lack for biomarkers of cardiotoxicity besides the cardiac dysfunction. The objective of the present study was to compare [18F]FDG and [123I]MIBG (metaiodobenzylguanidine) in a longitudinal study in a doxorubicin-induced cardiot...

Full description

Bibliographic Details
Main Authors: Alexandra Oudot, Alan Courteau, Mélanie Guillemin, Jean-Marc Vrigneaud, Paul Michael Walker, François Brunotte, Alexandre Cochet, Bertrand Collin
Format: Article
Language:English
Published: SpringerOpen 2021-09-01
Series:EJNMMI Research
Subjects:
Doxorubicin
Cardiotoxicity
Heart
[18F]FDG
[123I]MIBG
Online Access:https://doi.org/10.1186/s13550-021-00835-1

Internet

https://doi.org/10.1186/s13550-021-00835-1

Similar Items